Business ❯ Pharmaceuticals

Biotechnology

Drug Development Acquisitions Clinical Trials Mergers and Acquisitions Clinical Development Partnerships Vaccine Development Gene Editing Cancer Treatment Biosimilars

Regeneron Strikes Parabilis Deal to Develop Antibody-Helicon Drugs

The pact backs Parabilis’ Helicon peptides to reach protein targets inside cells once seen as out of reach.

FDA Clears Vepdegestrant, First PROTAC Cancer Drug, for ESR1‑Mutated Breast Cancer

Lilly and Profluent Strike AI Gene-Editing Pact Worth Up to $2.25 Billion

Revolution Medicines’ Pancreatic Cancer Drug Lands ASCO Plenary After Phase 3 Survival Gain

Eli Lilly to Buy Kelonia for Up to $7 Billion to Gain In‑Vivo CAR‑T Platform

Definium Therapeutics Jumps to 52-Week High After Trump Order on Psychedelic Treatments

OpenAI Launches GPT-Rosalind, a Biology-Tuned AI for Drug Discovery

Regeneron and Telix Form 50/50 Partnership to Develop Targeted Radiopharmaceuticals

South Africa Receives First Lenacapavir Shipment for HIV Prevention

Simulations Plus Beats Q2, Lowers FY2026 Profit Outlook

Biocon Targets One in Five Insulin Users as It Pushes for Global Lead

Ultragenyx Hit With Securities Class Action Over Failed Phase III Trials

Novartis to Acquire Excellergy in Up to $2 Billion Deal for Next-Gen Anti-IgE

Sarepta Reports Early siRNA Data Showing Muscle Delivery as Shares Surge

FDA Approves First Glucocorticoid Receptor Blocker for Platinum-Resistant Ovarian Cancer

Gilead to Buy Ouro Medicines for $1.675 Billion Upfront to Advance Autoimmune T‑Cell Engager

Pfizer–Valneva Lyme Vaccine Shows Over 70% Efficacy but Misses Primary Endpoint

Trump Promotes Drug-Price Push and Reshoring on Cincinnati-Area Swing, Backs Massie Challenger

Xenon to Present Topline X-TOLE2 Phase 3 Results in Focal Onset Seizures at 8 A.M. ET Today

Novo Nordisk Licenses Vivtex Platform in $2.1 Billion Push for Oral Obesity and Diabetes Drugs